Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | CNR1 | P21554 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31544851 | 1.00 | CNR2 (1.00) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL31545774 | 1.00 | CNR2 (1.00) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL22783274 | 0.84 | CNR2 (0.78) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL31544945 | 0.81 | CNR2 (0.67) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL16124349 | 0.80 | CNR2 (0.94) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL11665838 | 0.80 | CNR2 (0.69) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL6972822 | 0.80 | CNR2 (0.67) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL31545532 | 0.80 | CNR2 (0.67) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL11736739 | 0.80 | CNR2 (0.66) | CNR2CNR1MEN1GAAKMT2A | |
| SCHEMBL10507481 | 0.80 | CNR2 (0.66) | CNR2CNR1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218653-A1 | CARTRIDGE FOR VAPOR-PHASE CANNABINOID REACTIONS WITHIN A DEVICE | CANOPY GROWTH CORPORATION (CA) | 2022-07-14 | — | — | US | disclosed |
| US-4126694-A | TETRAHYDRODIBENZOPYRANS | SISA INCORPORATED (US) | 1978-11-21 | — | — | US | disclosed |
| US-4051152-A | TRANQUILIZERS, ANALGESICS | SHARPS ASSOCIATES (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218653-A1 | CARTRIDGE FOR VAPOR-PHASE CANNABINOID REACTIONS WITHIN A DEVICE | CNR1, CNR2, FAAH | CNR2 2/4885CNR1 1/4885MEN1 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.